Eli Lilly shares fall 2.44% intraday as Novo Nordisk faces competition, impacting Eli Lilly's market position.

miércoles, 6 de agosto de 2025, 11:52 am ET1 min de lectura
LLY--
Eli Lilly And Company dropped 2.44% intraday, with Novo Nordisk, a major competitor, announcing cost-cutting measures due to increased competition from Eli Lilly and other firms. Novo Nordisk's CEO replacement and warnings on profits further indicate market challenges, which may have contributed to the decline in Eli Lilly's stock price.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios